Primary tumor growth produced by the 231-BR cell line, which contains an exon 11 mutation of B-Raf, was maximally sensitive to pazopanib in vitro and significantly inhibited by pazopanib 9 days after treatment with the highest drug dose (p = 0.009). The gene discussed is BRAF; the disease is neoplasm.